JUL 30, 2019 11:39 AM PDT

Treating Drug-Resistant Acute Lymphoblastic Leukemia

WRITTEN BY: Nouran Amin

New therapeutics may have helped improve survival rates for acute lymphoblastic leukemia patients but some patients still remain unresponsive to existing treatment regimens. To make matters worse, drug resistance is not the only concern--the risk of drug-related toxicities among patients has pushed researchers to seek safer and effective therapeutics.

Now, scientists from Case Western Reserve University School of Medicine have developed a novel combination treatment regimen that enhances immune system function and improve the ability to kill leukemia’s that do not respond to standard protocol treatments. Findings were published in Cancer Immunology Research and describes the use of mouse models to illustrate how an antibody attaches to a specific protein on the cell surface of acute lymphoblastic leukemia cells and creates a bridge by attaching to a natural killer that quickly works to eradicate the cancer cell.

"If we started to treat mice with the antibody early during disease development, leukemia was almost eradicated by this treatment method; however, if treatment was administered late when the tumor had grown and established its own microenvironment, the antibody alone was less effective," said Parameswaran, who is also a member of the Case Comprehensive Cancer Center and a St. Baldrick's Scholar. "There was a clear negative effect of the tumor microenvironment on natural killer cell killing capacity," Parameswaran said. "So, we added a TGF-beta receptor inhibitor to our antibody treatment regimen."

Watch this video below to learn more on acute lymphoblastic leukemia:

The treatment uses BAFF-R antibody, which attaches to the BAFF-R protein on cancer cells. The antibody is currently being used to treat autoimmune diseases and rheumatoid arthritis in two clinical trial studies.

"We looked at BAFF-R expression in a small group of 16 patients and all of them expressed this receptor. It's promising as a therapeutic avenue for late-stage disease" Parameswaran said. Data from larger patient sets will help us draw a definitive conclusion."

Source: Case Western University

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 25, 2021
Drug Discovery & Development
Future COVID-19 Targets Rapidly Identified with Computer Simulations
FEB 25, 2021
Future COVID-19 Targets Rapidly Identified with Computer Simulations
A recent mechanism as detailed in the novel SARS-CoV2 that causes COVID-19 could help scientists find new therapeutics. ...
MAR 02, 2021
Coronavirus
Vitamin B6 May Reduce the Risk of Severe COVID-19
MAR 02, 2021
Vitamin B6 May Reduce the Risk of Severe COVID-19
Scientists are trying to learn more about whether any nutrients, like vitamins C, D, and now B6, can provide some protec ...
MAR 21, 2021
Microbiology
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
MAR 21, 2021
Potent Drug Rapidly Clears Drug-Resistant Gonorrhea in Mouse Model
A mouse model has shown that it's possible to clear a multi-drug resistant gonorrhea with only one dose of antibioti ...
MAR 30, 2021
Drug Discovery & Development
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
MAR 30, 2021
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
Researchers from the Karolinska Institute and Umea University in Sweden have found that a commonly recommended group of ...
MAY 27, 2021
Neuroscience
Research Less Likely to Be True is Cited More
MAY 27, 2021
Research Less Likely to Be True is Cited More
Researchers from the University of California San Diego have found that non-replicable data is cited 153 times more ofte ...
JUN 03, 2021
Immunology
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
JUN 03, 2021
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
Nanobodies are small fragments of monoclonal antibodies that from a therapeutic perspective are more stable and cheaper ...
Loading Comments...